HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
Status:
Recruiting
Trial end date:
2024-12-05
Target enrollment:
Participant gender:
Summary
The efficacy and safety of HAIC combined with tyrosine kinase inhibitor and immunotherapy
have been proved by the clinical research. In this single-arm, open-label, prospective study,
for those patients with unresectable primary HCC, in the case of failure of TACE treatment,
the combination of HAIC, TKI and immunotherapy is expected to bring new breakthroughs.